Brain Resource: Revolutionizing a Common Perception of Depression
Their concept is simple: positive thoughts reduce depression. Train your brain to increase positive thoughts.
depression
IntelGenx’s Anti-Depressant, CPI-300, Receives FDA Approval
IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.
Breakthrough Study Indicates CNS Response’s Referenced-EEG Enables Physicians to Significantly Improve Success Rates in Treating Depression
According to The Journal of Psychiatric Research, a breakthrough study by CNS Response, Inc. (OTCBB: CNSO), reveals that physicians using CNS’s Referenced-EEG® (rEEG), an online reference database, were able to significantly improve their success in treating patients with depression, including patients with treatment-resistant depression.
OneMedForum New York 2010 Successfully Brings Together Innovators and Investors
The mid-year conference’s goal was to bring together a promising group of 75 private and microcap companies in 25 different healthcare sectors with a prominent group of European and U.S. institutional investor groups.
OneMedForum to Highlight the Newest, Most Promising Med Tech Innovations
OneMedPlace announced that it will showcase to investors and entrepreneurs the newest and most promising new medical technologies in the region.
Drug Compliance a Major Issue for Psych Patients
Compliance is a vital part of managing mental health issues, considering the widespread use of psychiatric medications in the U.S.
Two Pharma Companies to Offer Discounted Shares
Repros and Targacept have announced plans to offer shares in their respective companies at a reduced cost.
Antidepressant Use Doubled In U.S. Over Past Decade
Antidepressant use in the U.S. nearly doubled between 1996 and 2005, according to a new report.
CNS Closes $1M Bridge Loan, Completes Clinical Trial Enrollment
The money will allow CNS Response, based in Costa Mesa, Calif., to complete an upcoming depression study.